Scribe Therapeutics Inc. (SCTX) Income Statement
SCTX 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsSCTX revenue and net income
Where SCTX's revenue goes
2025Each bar shows an amount and its share of revenue. SCTX kept −42.6% of revenue as net income.
SCTX profit margins
SCTX growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +86.7% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
SCTX quarterly EPS vs estimates
Scribe Therapeutics beat the analyst EPS estimate in 1 of the last 1 quarters. Next report: December 2, 2026 (estimate $-0.42).
SCTX income statement
| 2025 | 2024 | |
|---|---|---|
| Revenue | $51.2M | $27.4M |
| Research & development | $60.8M | $57.1M |
| Sales, general & admin | $16.4M | $13.2M |
| Total operating expenses | $77.2M | $70.2M |
| Operating income | −$26.1M | −$42.8M |
| Interest income | $3.3M | $6.2M |
| Interest expense | $2.4M | $2.4M |
| Income before taxes | −$23.6M | −$37.6M |
| Net income | −$21.8M | −$47.8M |
| EBITDA | −$18.1M | −$32.3M |
| Operating margin | −50.9% | −156.2% |
| Net margin | −42.6% | −174.3% |
| Jun '26 | Mar '26 | Jun '25 | Mar '25 | |
|---|---|---|---|---|
| Revenue | $1.9M | $2.2M | $4.9M | $17.1M |
| Research & development | $8.8M | $11.3M | $13.9M | $16.0M |
| Sales, general & admin | $2.5M | $3.4M | $2.6M | $6.7M |
| Total operating expenses | $11.3M | $14.7M | $16.5M | $22.7M |
| Operating income | −$9.4M | −$12.4M | −$11.6M | −$5.6M |
| Interest income | $383,000 | $515,000 | $880,000 | $1.1M |
| Interest expense | $276,000 | $598,000 | $598,000 | $598,000 |
| Income before taxes | −$6.3M | −$17.1M | −$10.6M | −$3.7M |
| Net income | −$6.5M | −$17.3M | −$9.9M | −$3.4M |
| EBITDA | −$5.2M | −$15.7M | −$9.2M | −$2.3M |
| EPS (diluted) | −$3.84 | — | — | — |
| Operating margin | −489.8% | −556.5% | −237.4% | −32.4% |
| Net margin | −337.7% | −776.8% | −202.2% | −20.0% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in SCTX's financial statements (latest annual report filed —); data from EODHD. Sales, general & administrative expenses include sales and marketing.
SCTX financial results
In fiscal year 2025 (ended December 31, 2025), Scribe Therapeutics reported revenue of $51.2 million, up 86.7% from the year before. It had a net loss of $21.8 million, a net profit margin of −42.6%.
See the SCTX stock overview for the latest quote and news, or the SCTX chart for price history and technical indicators.
SCTX income statement FAQ
What is Scribe Therapeutics's annual revenue?
Scribe Therapeutics reported total revenue of $51.2 million for fiscal year 2025, which ended on December 31, 2025. That was up 86.7% from $27.4 million the previous year.
Is Scribe Therapeutics profitable?
No. Scribe Therapeutics reported a net loss of $21.8 million in fiscal 2025, a net profit margin of −42.6%; its operating margin was −50.9%.
How much does Scribe Therapeutics spend on research and development?
Scribe Therapeutics spent $60.8 million on research and development in fiscal 2025, 118.8% of revenue.
When will Scribe Therapeutics report its next earnings?
Scribe Therapeutics is expected to report results for the quarter ending September 30, 2026 on December 2, 2026.
When does Scribe Therapeutics's fiscal year end?
Scribe Therapeutics's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025.